NovaBridge Biosciences Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Hagler Mark Arnold, was filed 28 Apr 2026.
NovaBridge Biosciences: what insiders have been doing
NovaBridge Biosciences is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 20 October 2026, brought 16 filings signed by 8 insiders.
Both sides are active: 1 purchase worth €494k and 5 sales worth €84k, from 1 insider and 3 insiders respectively. On balance, insiders were net buyers of €410k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €494k, bought by Hagler Mark Arnold and made public on 28 April 2026 (0.24% of market cap).
The latest purchase dates back some time: it was published 194 days ago, on 28 April 2026. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,459 companies, median 22 filings), a count of 16 filings is below the norm. Looking back to 2026, when coverage begins, insiders filed 1 purchase and 5 sales.
In the same market, recent insider purchases at Applied Digital Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -25.5%Entry US$2.35 · Close at T+90 US$1.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,271 sharesOrdinary SharesSEC:0002115245-26-000004:0
- 8,209 shares@ US$0.710.0036% mcap50.1% of flowOrdinary SharesSEC:0002089237-26-000008:1
- 23,695 sharesOrdinary SharesSEC:0002089237-26-000008:0
- 3,569 shares@ US$1.62470.0036% mcap49.9% of flowCommon StockSEC144:0001973379-26-000341
- 107,978 shares@ US$0.740.049% mcap50.2% of flowOrdinary SharesSEC:0002109966-26-000008:0
- 46,947 shares@ US$1.69080.049% mcap49.8% of flowOrdinary SharesSEC144:0001973379-26-000336
- 235,136 sharesOrdinary SharesSEC:0002109966-26-000006:0
- 104,236 sharesOrdinary SharesSEC:0002109966-26-000006:1
- 9,382 sharesOrdinary SharesSEC:0002114309-26-000007:0
- 3,282 shares@ US$0.790.0016% mcap39.1% of flowOrdinary SharesSEC:0002114309-26-000007:1
- 17,218 sharesOrdinary SharesSEC:0001992908-26-000013:0
- 4,485 shares@ US$0.890.0025% mcap60.9% of flowOrdinary SharesSEC:0002114309-26-000005:1
- 12,432 sharesOrdinary SharesSEC:0002114309-26-000005:0
- 23,695 sharesOrdinary SharesSEC:0002089237-26-000006:0
- 8,494 shares@ US$0.6632.6% of flowOrdinary SharesSEC:0002089237-26-000006:1
- 230,000 shares@ US$2.510.24% mcap100.0% of flowOrdinary SharesSEC:0001193125-26-186924:0Canonical exit: 23 Jul 2026 (T+90)
16 of 16 declarations
About NovaBridge Biosciences
NovaBridge Biosciences is a company listed on the XNAS market, specializing in the development of innovative biopharmaceutical solutions. It focuses on research and commercialization of treatments for complex diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
